Cyrille Hulin - Concepedia

Author

Cyrille Hulin

Hôpital Cardiologique du Haut-Lévêque ORCID

Also Known As

C Hulin, C. Hulin, Cyrille HULIN, Cyrille Hulin, Hulin, C., Hulin, Cyrille, Philippe Moreau

307

Publications

12.7K

Citations

H-Index

Concepts

All Affiliations

Hôpital Cardiologique du Haut-Lévêque Janssen (United States)Centre Hospitalier Universitaire de Nantes Institut universitaire du cancer de Toulouse Oncopole Inserm

About

Cyrille Hulin is an author at Hôpital Cardiologique du Haut-Lévêque specializing in oncology, medicine, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	36	5.1K
2	Health Sciences	19	27	3K
3	Engineering	1	1	31
4	Public Health	1	1	19
5	Blood Transplantation	1	1	52

Cyrille Hulin

102

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma Michel Attal, Thierry Façon, François Guilhot, New England Journal of Medicine	2003	973
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Thierry Façon, Shaji Kumar, Torben Plesner, New England Journal of Medicine	2019	947
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau, Michel Attal, Cyrille Hulin, The Lancet Hematological MalignancyRadiation OncologyMedicineImmunologyHematology	2019	922
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri, New England Journal of Medicine	2014	780
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Sagar Lonial, Hans C. Lee, Ashraf Badros, The Lancet Oncology Hematological MalignancyMedicinePathologyBelantamab MafodotinCancer Treatment	2019	772
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, The Lancet Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy	2019	620
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, New England Journal of Medicine	2023	435
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre, Blood	2018	408
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial Cyrille Hulin, Thierry Façon, Philippe Rodon, Journal of Clinical Oncology	2009	380
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Frédéric Garban, Michel Attal, Mauricette Michallet, Blood	2006	370

Page 1